Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 289

1.

Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats.

Di Martino MT, Arbitrio M, Caracciolo D, Scionti F, Tagliaferri P, Tassone P.

Mol Ther Nucleic Acids. 2020 Feb 8;20:73-85. doi: 10.1016/j.omtn.2020.01.036. [Epub ahead of print]

2.

Influence of the Fabrication Accuracy of Hot-Embossed PCL Scaffolds on Cell Growths.

Limongi T, Dattola E, Botta C, Coluccio ML, Candeloro P, Cucè M, Scopacasa B, Gallo Cantafio ME, Critello CD, Pullano SA, Fiorillo AS, Tagliaferri P, Tassone P, Lamanna E, Di Fabrizio E, Perozziello G.

Front Bioeng Biotechnol. 2020 Feb 14;8:84. doi: 10.3389/fbioe.2020.00084. eCollection 2020.

3.

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma.

Caracciolo D, Scionti F, Juli G, Altomare E, Golino G, Todoerti K, Grillone K, Riillo C, Arbitrio M, Iannone M, Morelli E, Amodio N, Di Martino MT, Rossi M, Neri A, Tagliaferri P, Tassone P.

Haematologica. 2020 Feb 20. pii: haematol.2019.240713. doi: 10.3324/haematol.2019.240713. [Epub ahead of print]

4.

Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease.

Musolino V, Gliozzi M, Scarano F, Bosco F, Scicchitano M, Nucera S, Carresi C, Ruga S, Zito MC, Maiuolo J, Macrì R, Amodio N, Juli G, Tassone P, Mollace R, Caffrey R, Marioneaux J, Walker R, Ehrlich J, Palma E, Muscoli C, Bedossa P, Salvemini D, Mollace V, Sanyal AJ.

Sci Rep. 2020 Feb 13;10(1):2565. doi: 10.1038/s41598-020-59485-3.

5.

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias.

Morelli E, Gullà A, Rocca R, Federico C, Raimondi L, Malvestiti S, Agosti V, Rossi M, Costa G, Giavaresi G, Azab KA, Cagnetta A, Cea M, Tagliaferri P, Neri A, Munshi NC, Viglietto G, Tassone P, Amodio N.

Cancers (Basel). 2020 Jan 30;12(2). pii: E320. doi: 10.3390/cancers12020320. Review.

6.

Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab.

Nardone V, Tini P, Pastina P, Botta C, Reginelli A, Carbone SF, Giannicola R, Calabrese G, Tebala C, Guida C, Giudice A, Barbieri V, Tassone P, Tagliaferri P, Cappabianca S, Capasso R, Luce A, Caraglia M, Mazzei MA, Pirtoli L, Correale P.

Oncol Lett. 2020 Feb;19(2):1559-1566. doi: 10.3892/ol.2019.11220. Epub 2019 Dec 16.

7.

Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221.

Di Martino MT, Arbitrio M, Fonsi M, Erratico CA, Scionti F, Caracciolo D, Tagliaferri P, Tassone P.

Cancers (Basel). 2019 Dec 19;12(1). pii: E27. doi: 10.3390/cancers12010027.

8.

GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up.

Caraglia M, Correale P, Giannicola R, Staropoli N, Botta C, Pastina P, Nesci A, Caporlingua N, Francini E, Ridolfi L, Mini E, Roviello G, Ciliberto D, Agostino RM, Strangio A, Azzarello D, Nardone V, Falzea A, Cappabianca S, Bocchetti M, D'Arrigo G, Tripepi G, Tassone P, Addeo R, Giordano A, Pirtoli L, Francini G, Tagliaferri P.

Front Oncol. 2019 Nov 8;9:1102. doi: 10.3389/fonc.2019.01102. eCollection 2019.

9.

An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery.

Catuogno S, Di Martino MT, Nuzzo S, Esposito CL, Tassone P, de Franciscis V.

Mol Ther Nucleic Acids. 2019 Dec 6;18:981-990. doi: 10.1016/j.omtn.2019.10.021. Epub 2019 Oct 28.

10.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.

Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.

Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.

11.

Complications, Mortality, and Functional Decline in Patients 80 Years or Older Undergoing Major Head and Neck Ablation and Reconstruction.

Fancy T, Huang AT, Kass JI, Lamarre ED, Tassone P, Mantravadi AV, Alwani MM, Subbarayan RS, Bur AM, Worley ML, Graboyes EM, McMullen CP, Azoulay O, Wax MK, Cave TB, Al-Khudari S, Abello EH, Higgins KM, Ryan JT, Orzell SC, Goldman RA, Vimawala S, Fernandes RP, Abdelmalik M, Rajasekaran K, L'Esperance HE, Kallogjeri D, Rich JT.

JAMA Otolaryngol Head Neck Surg. 2019 Oct 10. doi: 10.1001/jamaoto.2019.2768. [Epub ahead of print]

PMID:
31600390
12.

Metformin effects on FOXP3+ and CD8+ T cell infiltrates of head and neck squamous cell carcinoma.

Amin D, Richa T, Mollaee M, Zhan T, Tassone P, Johnson J, Luginbuhl A, Cognetti D, Martinez-Outschoorn U, Stapp R, Solomides C, Rodeck U, Curry J.

Laryngoscope. 2019 Oct 8. doi: 10.1002/lary.28336. [Epub ahead of print]

PMID:
31593308
13.

A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.

Catalano R, Rocca R, Juli G, Costa G, Maruca A, Artese A, Caracciolo D, Tagliaferri P, Alcaro S, Tassone P, Amodio N.

Eur J Med Chem. 2019 Dec 1;183:111715. doi: 10.1016/j.ejmech.2019.111715. Epub 2019 Sep 17.

PMID:
31550663
14.

Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma.

Taiana E, Favasuli V, Ronchetti D, Todoerti K, Pelizzoni F, Manzoni M, Barbieri M, Fabris S, Silvestris I, Gallo Cantafio ME, Platonova N, Zuccalà V, Maltese L, Soncini D, Ruberti S, Cea M, Chiaramonte R, Amodio N, Tassone P, Agnelli L, Neri A.

Leukemia. 2020 Jan;34(1):234-244. doi: 10.1038/s41375-019-0542-5. Epub 2019 Aug 19.

PMID:
31427718
15.

Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma.

Juli G, Oliverio M, Bellizzi D, Gallo Cantafio ME, Grillone K, Passarino G, Colica C, Nardi M, Rossi M, Procopio A, Tagliaferri P, Tassone P, Amodio N.

Cancers (Basel). 2019 Jul 16;11(7). pii: E990. doi: 10.3390/cancers11070990.

16.

Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab.

Giannicola R, D'Arrigo G, Botta C, Agostino R, Del Medico P, Falzea AC, Barbieri V, Staropoli N, Del Giudice T, Pastina P, Nardone V, Monoriti M, Calabrese G, Tripepi G, Pirtoli L, Tassone P, Tagliaferri P, Correale P.

Mol Clin Oncol. 2019 Jul;11(1):81-90. doi: 10.3892/mco.2019.1859. Epub 2019 May 16.

17.

Cigarette Smoke Induces Metabolic Reprogramming of the Tumor Stroma in Head and Neck Squamous Cell Carcinoma.

Domingo-Vidal M, Whitaker-Menezes D, Martos-Rus C, Tassone P, Snyder CM, Tuluc M, Philp N, Curry J, Martinez-Outschoorn U.

Mol Cancer Res. 2019 Sep;17(9):1893-1909. doi: 10.1158/1541-7786.MCR-18-1191. Epub 2019 Jun 25.

18.

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.

Crit Rev Oncol Hematol. 2019 Aug;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. Epub 2019 May 25.

19.

miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma.

Misso G, Zarone MR, Lombardi A, Grimaldi A, Cossu AM, Ferri C, Russo M, Vuoso DC, Luce A, Kawasaki H, Di Martino MT, Virgilio A, Festa A, Galeone A, De Rosa G, Irace C, Donadelli M, Necas A, Amler E, Tagliaferri P, Tassone P, Caraglia M.

Mol Ther Nucleic Acids. 2019 Jun 7;16:391-406. doi: 10.1016/j.omtn.2019.02.023. Epub 2019 Mar 13.

20.

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.

Cucè M, Gallo Cantafio ME, Siciliano MA, Riillo C, Caracciolo D, Scionti F, Staropoli N, Zuccalà V, Maltese L, Di Vito A, Grillone K, Barbieri V, Arbitrio M, Di Martino MT, Rossi M, Amodio N, Tagliaferri P, Tassone P, Botta C.

J Hematol Oncol. 2019 Mar 21;12(1):32. doi: 10.1186/s13045-019-0714-9.

21.

Thermistor-controlled subdermal skin tightening for the aging face: Clinical outcomes and efficacy.

Sanan A, Hjelm N, Tassone P, Krein H, Heffelfinger RN.

Laryngoscope Investig Otolaryngol. 2018 Dec 20;4(1):18-23. doi: 10.1002/lio2.228. eCollection 2019 Feb.

22.

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma.

Amodio N, Gallo Cantafio ME, Botta C, Agosti V, Federico C, Caracciolo D, Ronchetti D, Rossi M, Driessen C, Neri A, Tagliaferri P, Tassone P.

Cancers (Basel). 2019 Feb 18;11(2). pii: E236. doi: 10.3390/cancers11020236.

23.

Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides.

Olivito F, Amodio N, Di Gioia ML, Nardi M, Oliverio M, Juli G, Tassone P, Procopio A.

Medchemcomm. 2018 Dec 5;10(1):116-119. doi: 10.1039/c8md00503f. eCollection 2019 Jan 1.

24.

Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study.

Arbitrio M, Scionti F, Altomare E, Di Martino MT, Agapito G, Galeano T, Staropoli N, Iuliano E, Grillone F, Fabiani F, Caracciolo D, Cannataro M, Arpino G, Santini D, Tassone P, Tagliaferri P.

Clin Pharmacol Ther. 2019 Aug;106(2):422-431. doi: 10.1002/cpt.1391. Epub 2019 Mar 28.

PMID:
30739312
25.

Office-based transnasal esophagoscopy biopsies for histological diagnosis of head and neck patients.

Mohammed H, Del Pero M, Coates M, Masterson L, Tassone P, Burrows S, Nassif R.

Laryngoscope. 2019 Dec;129(12):2721-2726. doi: 10.1002/lary.27714. Epub 2018 Dec 13.

PMID:
30548865
26.

Taking Free Flap Surgery Abroad: A Collaborative Approach to a Complex Surgical Problem.

Swendseid B, Tassone P, Gilles PJ, Pavrette M, Stewart M, Babatope M, Weed D, Cognetti D, Luginbuhl A, Curry J.

Otolaryngol Head Neck Surg. 2019 Mar;160(3):426-428. doi: 10.1177/0194599818818459. Epub 2018 Dec 11.

PMID:
30526295
27.

Metformin Clinical Trial in HPV+ and HPV- Head and Neck Squamous Cell Carcinoma: Impact on Cancer Cell Apoptosis and Immune Infiltrate.

Curry JM, Johnson J, Mollaee M, Tassone P, Amin D, Knops A, Whitaker-Menezes D, Mahoney MG, South A, Rodeck U, Zhan T, Harshyne L, Philp N, Luginbuhl A, Cognetti D, Tuluc M, Martinez-Outschoorn U.

Front Oncol. 2018 Oct 11;8:436. doi: 10.3389/fonc.2018.00436. eCollection 2018.

28.

The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.

Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P.

Crit Rev Oncol Hematol. 2018 Nov;131:83-89. doi: 10.1016/j.critrevonc.2018.08.011. Epub 2018 Sep 3. Review.

PMID:
30293710
29.

Ossicular chain mobilisation versus reconstruction in surgery for isolated malleus and/or incus fixation: systematic review and meta-analysis.

Crutcher WL, Tassone P, Pelosi S.

J Laryngol Otol. 2018 Oct;132(10):858-865. doi: 10.1017/S0022215118001494. Epub 2018 Oct 5. Review.

PMID:
30289092
30.

Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma.

Taiana E, Ronchetti D, Favasuli V, Todoerti K, Manzoni M, Amodio N, Tassone P, Agnelli L, Neri A.

Haematologica. 2019 Feb;104(2):e72-e76. doi: 10.3324/haematol.2018.201301. Epub 2018 Sep 13. No abstract available.

31.

The potential role of miRNAs in multiple myeloma therapy.

Caracciolo D, Montesano M, Altomare E, Scionti F, Di Martino MT, Tagliaferri P, Tassone P.

Expert Rev Hematol. 2018 Oct;11(10):793-803. doi: 10.1080/17474086.2018.1517041. Epub 2018 Sep 12. Review.

PMID:
30148649
32.

APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.

Cho RJ, Alexandrov LB, den Breems NY, Atanasova VS, Farshchian M, Purdom E, Nguyen TN, Coarfa C, Rajapakshe K, Prisco M, Sahu J, Tassone P, Greenawalt EJ, Collisson EA, Wu W, Yao H, Su X, Guttmann-Gruber C, Hofbauer JP, Hashmi R, Fuentes I, Benz SC, Golovato J, Ehli EA, Davis CM, Davies GE, Covington KR, Murrell DF, Salas-Alanis JC, Palisson F, Bruckner AL, Robinson W, Has C, Bruckner-Tuderman L, Titeux M, Jonkman MF, Rashidghamat E, Lwin SM, Mellerio JE, McGrath JA, Bauer JW, Hovnanian A, Tsai KY, South AP.

Sci Transl Med. 2018 Aug 22;10(455). pii: eaas9668. doi: 10.1126/scitranslmed.aas9668.

PMID:
30135250
33.

miR-22 suppresses DNA ligase III addiction in multiple myeloma.

Caracciolo D, Di Martino MT, Amodio N, Morelli E, Montesano M, Botta C, Scionti F, Talarico D, Altomare E, Gallo Cantafio ME, Zuccalà V, Maltese L, Todoerti K, Rossi M, Arbitrio M, Neri A, Tagliaferri P, Tassone P.

Leukemia. 2019 Feb;33(2):487-498. doi: 10.1038/s41375-018-0238-2. Epub 2018 Aug 17.

34.

Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients.

Bryant LM, Daniels KE, Cognetti DM, Tassone P, Luginbuhl AJ, Curry JM.

Laryngoscope Investig Otolaryngol. 2018 Apr 16;3(3):169-177. doi: 10.1002/lio2.154. eCollection 2018 Jun. Review.

35.

Association of Positive Initial Margins With Survival Among Patients With Squamous Cell Carcinoma Treated With Total Laryngectomy.

Tassone P, Savard C, Topf MC, Keane W, Luginbuhl A, Curry J, Cognetti D.

JAMA Otolaryngol Head Neck Surg. 2018 Nov 1;144(11):1030-1036. doi: 10.1001/jamaoto.2018.1095.

36.

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.

Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P.

Blood. 2018 Sep 6;132(10):1050-1063. doi: 10.1182/blood-2018-03-836601. Epub 2018 Jul 11.

37.

Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation.

Raimondi L, De Luca A, Giavaresi G, Barone A, Tagliaferri P, Tassone P, Amodio N.

Curr Med Chem. 2020;27(2):187-215. doi: 10.2174/0929867325666180629153141.

PMID:
29956610
38.

Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.

Correale P, Botta C, Staropoli N, Nardone V, Pastina P, Ulivieri C, Gandolfo C, Baldari TC, Lazzi S, Ciliberto D, Giannicola R, Fioravanti A, Giordano A, Zappavigna S, Caraglia M, Tassone P, Pirtoli L, Cusi MG, Tagliaferri P.

Oncotarget. 2018 Apr 17;9(29):20539-20554. doi: 10.18632/oncotarget.24993. eCollection 2018 Apr 17.

39.

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches.

Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P.

J Hematol Oncol. 2018 May 8;11(1):63. doi: 10.1186/s13045-018-0606-4. Review.

40.

Mouse models of multiple myeloma: technologic platforms and perspectives.

Rossi M, Botta C, Arbitrio M, Grembiale RD, Tagliaferri P, Tassone P.

Oncotarget. 2018 Apr 13;9(28):20119-20133. doi: 10.18632/oncotarget.24614. eCollection 2018 Apr 13. Review.

41.

miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling.

Santolla MF, Lappano R, Cirillo F, Rigiracciolo DC, Sebastiani A, Abonante S, Tassone P, Tagliaferri P, Di Martino MT, Maggiolini M, Vivacqua A.

J Exp Clin Cancer Res. 2018 May 2;37(1):94. doi: 10.1186/s13046-018-0767-6.

42.

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).

Waldschmidt JM, Keller A, Ihorst G, Grishina O, Müller S, Wider D, Frey AV, King K, Simon R, May A, Tassone P, Duyster J, Jung M, Raje N, Wäsch R, Engelhardt M.

Haematologica. 2018 Oct;103(10):e473-e479. doi: 10.3324/haematol.2018.189969. Epub 2018 Apr 19. No abstract available.

43.

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis.

Ciliberto D, Staropoli N, Caglioti F, Chiellino S, Ierardi A, Ingargiola R, Botta C, Arbitrio M, Correale P, Tassone P, Tagliaferri P.

Crit Rev Oncol Hematol. 2018 May;125:69-77. doi: 10.1016/j.critrevonc.2018.03.003. Epub 2018 Mar 9. Review.

PMID:
29650279
44.

Buccal space malignancy in the setting of chronic sialadenitis: A report of 2 cases.

Bryant LM, Tassone P, Curry J, Luginbuhl A, Cognetti D.

Ear Nose Throat J. 2018 Jan-Feb;97(1-2):E12-E14.

PMID:
29493724
45.

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.

Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E, Raimondi L, Caracciolo D, Zuccalà V, Rossi M, Neri A, Munshi NC, Tagliaferri P, Tassone P.

Leukemia. 2018 Sep;32(9):1948-1957. doi: 10.1038/s41375-018-0067-3. Epub 2018 Feb 22.

46.

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.

Botta C, Ciliberto D, Rossi M, Staropoli N, Cucè M, Galeano T, Tagliaferri P, Tassone P.

Blood Adv. 2017 Feb 27;1(7):455-466. doi: 10.1182/bloodadvances.2016003905. eCollection 2017 Feb 28.

47.

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma.

Stamato MA, Juli G, Romeo E, Ronchetti D, Arbitrio M, Caracciolo D, Neri A, Tagliaferri P, Tassone P, Amodio N.

Oncotarget. 2017 Nov 20;8(63):106527-106537. doi: 10.18632/oncotarget.22507. eCollection 2017 Dec 5.

48.

Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC-MS/MS.

Franzoni S, Vezzelli A, Turtoro A, Solazzo L, Greco A, Tassone P, Di Martino MT, Breda M.

J Pharm Biomed Anal. 2018 Feb 20;150:300-307. doi: 10.1016/j.jpba.2017.12.027. Epub 2017 Dec 15.

PMID:
29268195
49.

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.

Zarone MR, Misso G, Grimaldi A, Zappavigna S, Russo M, Amler E, Di Martino MT, Amodio N, Tagliaferri P, Tassone P, Caraglia M.

Sci Rep. 2017 Dec 20;7(1):17949. doi: 10.1038/s41598-017-18186-0.

50.

Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment.

Raimondi L, De Luca A, Costa V, Amodio N, Carina V, Bellavia D, Tassone P, Pagani S, Fini M, Alessandro R, Giavaresi G.

Oncotarget. 2017 Aug 3;8(59):100831-100851. doi: 10.18632/oncotarget.19852. eCollection 2017 Nov 21. Review.

Supplemental Content

Loading ...
Support Center